Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.

Share your partnering idea

Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.

 

Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.

Our Values

Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.

 

What does it really make Menarini unique? The diversity and authenticity of our key resource - the People.
Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.

Available positions on Linkedin

Menarini employees make all the difference, every day.

 

Colorectal Cancers

Slider oncology

Colorectal Cancers

Colorectal cancer remains a leading cause of cancer-related death worldwide despite the advances attributed to cancer screening programs, improved surgical techniques and effective chemotherapy. The introduction of targeted therapies and immunotherapy together with better biomarker risk stratification methods have led to a qualified improvement in survival and many challenges remain. At Menarini we are assessing how best to improve drug development strategies from the metastatic to the adjuvant setting using rationale combinations of targeted therapies in different subtypes of colorectal cancer. 

oncology